Oral drugs
01General
Hit healthy tissue. The effect fades.
Neurotherapeutics
Molecule candidates inspired by neuromodulatory toxins. First target: tremor in Parkinson's disease.
The problem
The nervous system runs on precise signals. Disease scrambles them — and most drugs are too blunt to fix just one.
The consequence
Oral drugs
01Hit healthy tissue. The effect fades.
Injections
02Not specific. The relief fades.
Ultrasound
03Destroys tissue. No way back.
Surgery
04Invasive, and not for everyone.
So the symptoms come back.
The solution
Over millions of years, venoms evolved to act on the nervous system with a precision no drug has matched. We turn those toxins into therapeutic candidates.
Precise
Reversible
Tunable
How it works
Skip ↓Inspiration
Snakes. Spiders. Scorpions.
Challenge 1 · Stability
We control the disulfide bonds.
The idea
Drag it. It tunes the muscle signal.
Challenge 2 · Effectiveness
Where effectiveness is decided.
Therapeutic window
Our candidate is designed to act on a precise target and to be adjustable.
We are developing candidates, not offering a treatment.
Pipeline
α-Bungarotoxin is our lead candidate, in pre-clinical validation. Vm24 and Ts1 are in discovery & formulation. Stages are indicative.
Work with us
For investors
For biopharma
Questions
No. For now it is a palliative approach aimed at tremor. We are developing candidates, not a treatment.
Today's options are general, temporary or irreversible. We design a candidate that is specific, reversible and adjustable — aimed at the signal, not the healthy tissue.
When medication stops being enough, the options are few and each has a cost. Tremor in Parkinson's is a large, underserved place to start.
Venoms evolved over millions of years to act on the nervous system with a precision no drug has matched. We turn those toxins into therapeutic candidates.
Yes — stability depends on how their disulfide bonds form. Controlling that is what we know how to do.
Preclinical validation. Next: an animal model, co-developed with a biopharma partner.
One candidate today — α-Bungarotoxin, for Parkinson's. Change the channel and the toxin and the indication changes (Vm24, Ts1).
Preclinical validation, then an animal model with a biopharma, then clinical phases, registration and launch.
Investors who want to back one concrete molecule with a platform behind it, and biopharma partners to co-develop the first candidate.
Our vision
Imagine a world where what nature spent millions of years designing can calm disease in the nervous system.
For millions of patients.
Contact
Investors, biopharma partners and scientists: tell us who you are and what you have in mind. The founding team reads every message.